These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8454377)

  • 1. Effects of tissue plasminogen activator therapy on the frequency of acute right ventricular myocardial infarction associated with acute left ventricular infarction.
    Kalan JM; Gertz SD; Kragel AH; Berger PB; Roberts WC; Ryan TJ
    Int J Cardiol; 1993 Feb; 38(2):151-8. PubMed ID: 8454377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the thrombolysis in myocardial infarction [TIMI] II trial). The TIMI Research Group.
    Berger PB; Ruocco NA; Ryan TJ; Jacobs AK; Zaret BL; Wackers FJ; Frederick MM; Faxon DP
    Am J Cardiol; 1993 May; 71(13):1148-52. PubMed ID: 8097614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-type plasminogen activator therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction.
    Agati L; Voci P; Hickle P; Vizza DC; Autore C; Fedele F; Feinstein SB; Dagianti A
    J Am Coll Cardiol; 1998 Feb; 31(2):338-43. PubMed ID: 9462577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolytic therapy reduces the incidence of left ventricular thrombus after anterior myocardial infarction. Relationship to vessel patency and infarct size.
    Pizzetti G; Belotti G; Margonato A; Carlino M; Gerosa S; Carandente O; Chierchia SL
    Eur Heart J; 1996 Mar; 17(3):421-8. PubMed ID: 8737217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of early accelerated dose tissue plasminogen activator on in-hospital patency of the infarcted vessel in patients with acute right ventricular infarction.
    Giannitsis E; Potratz J; Wiegand U; Stierle U; Djonlagic H; Sheikhzadeh A
    Heart; 1997 Jun; 77(6):512-6. PubMed ID: 9227293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
    Van de Werf F; Arnold AE
    BMJ; 1988 Nov; 297(6660):1374-9. PubMed ID: 3146370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late reperfusion for acute myocardial infarction limits the dilatation of left ventricle without the reduction of infarct size.
    Hirayama A; Adachi T; Asada S; Mishima M; Nanto S; Kusuoka H; Yamamoto K; Matsumura Y; Hori M; Inoue M
    Circulation; 1993 Dec; 88(6):2565-74. PubMed ID: 8080490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: implications for the design of randomized trials of acute intervention.
    Gibbons RJ; Christian TF; Hopfenspirger M; Hodge DO; Bailey KR
    J Am Coll Cardiol; 1994 Sep; 24(3):616-23. PubMed ID: 8077529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma homocysteine level and left ventricular thrombus formation in acute anterior myocardial infarction patients following thrombolytic therapy with t-PA.
    Orhan AL; Okuyan E; Okcun B; Nurkalem Z; Sayar N; Soylu O; Uslu N; Yildiz A; Eren M; Mutlu H; Kucukoglu S
    Thromb Res; 2009 May; 124(1):65-9. PubMed ID: 19136146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial.
    Berger PB; Ruocco NA; Ryan TJ; Frederick MM; Podrid PJ
    J Am Coll Cardiol; 1993 Dec; 22(7):1773-9. PubMed ID: 8245327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender and acute myocardial infarction: is there a different response to thrombolysis?
    Woodfield SL; Lundergan CF; Reiner JS; Thompson MA; Rohrbeck SC; Deychak Y; Smith JO; Burton JR; McCarthy WF; Califf RM; White HD; Weaver WD; Topol EJ; Ross AM
    J Am Coll Cardiol; 1997 Jan; 29(1):35-42. PubMed ID: 8996292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of a negative exercise thallium test in the presence of a critical residual stenosis after thrombolysis for acute myocardial infarction.
    Sutton JM; Topol EJ
    Circulation; 1991 Apr; 83(4):1278-86. PubMed ID: 1901529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous diltiazem in acute myocardial infarction. Diltiazem as adjunctive therapy to activase (DATA) trial.
    Théroux P; Grégoire J; Chin C; Pelletier G; de Guise P; Juneau M
    J Am Coll Cardiol; 1998 Sep; 32(3):620-8. PubMed ID: 9741502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators.
    Gertz SD; Kragel AH; Kalan JM; Braunwald E; Roberts WC
    Am J Cardiol; 1990 Oct; 66(12):904-9. PubMed ID: 2121015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial.
    Wackers FJ; Terrin ML; Kayden DS; Knatterud G; Forman S; Braunwald E; Zaret BL
    J Am Coll Cardiol; 1989 Apr; 13(5):998-1005. PubMed ID: 2494246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction.
    Andreotti F; Roncaglioni MC; Hackett DR; Khan MI; Regan T; Haider AW; Davies GJ; Kluft C; Maseri A
    J Am Coll Cardiol; 1990 Dec; 16(7):1553-60. PubMed ID: 2123906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of thrombolysis on acute mitral regurgitation during evolving myocardial infarction. Experience from the Thrombolysis in Myocardial Infarction (TIMI) Trial.
    Lehmann KG; Francis CK; Sheehan FH; Dodge HT
    J Am Coll Cardiol; 1993 Sep; 22(3):714-9. PubMed ID: 8354803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of intravenous thrombolysis prior to percutaneous coronary intervention in reperfusion therapy for acute myocardial infarction].
    Uto K; Ota Y; Mizuno M; Nakamura A; Nakajima R; Endoh Y; Kasanuki H
    J Cardiol; 2002 Dec; 40(6):241-8. PubMed ID: 12528645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.